New Delhi:In a relief to Sun Pharma Laboratories Limited, the Bombay High Court has granted an interim injunction restraining Rambos Lifesciences Pvt. Ltd. from using the trademarks URSOCAL and URSOCAL-300, observing that they infringe upon Sun Pharma's registered liver drug trademark URSOCOL. The dispute revolves around Sun Pharma’s allegation that Rambos Lifesciences adopted and marketed pharmaceutical products under the marks URSOCAL and URSOCAL-300, which are “deceptively similar” to its well-established brand URSOCOL. Sun Pharma argued that such similarity was likely to create confusion among doctors, chemists, and patients in the sensitive pharmaceutical sector. Hearing the matter, Justice Arif S Doctor, through an order dated 20 August 2025, categorically restrained Rambos and its associates from infringing Sun Pharma’s rights. The Court observed that confusion in medicinal products could have serious consequences and therefore warranted urgent protection. The Court held: Earlier, on 16 July 2025, the Court had appointed the Court Receiver with wide powers to take possession of infringing goods, packaging materials, and related documents from the Respondents. The order stated, This order was executed on 6 August 2025, and the Court Receiver filed Report No. 371 of 2025 outlining the steps taken. Recording this, the Court adjourned the matter to 29 August 2025, as service on Defendant No.1 was noted to be incomplete. The matter remains sub judice, and the interim relief continues to operate until final adjudication Also Read: Mankind Pharma Wins PETKIND Trademark Battle, Court Orders Journal Advertisement Within Two Months To view the official order, click the link below: